Tectonic Therapeutic Inc (TECX)
Tectonic Therapeutic, Inc. is a biotechnology company listed on the NASDAQ under the ticker TECX. The company focuses on discovering and developing therapeutic proteins and antibodies designed to modulate the activity of G protein coupled receptors, or GPCRs. Its GEODe technology platform is intended to support the identification and development of GPCR-targeted biologic medicines. Tectonic’s lead program is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, a GPCR target associated with the hormone relaxin. The pipeline also includes TX2100 for hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for fibrosis, and additional GPCR modulator candidates. The company is headquartered in Watertown, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TECX
|
$19.55
|
0.7% Upside
|
Fair
|
$71
|
265.6% Upside
|
Bargain
|
Fair
|
0.0%
|
1.7x
|
379.6 M
|
157 M
|
1.1%
|
60.8%
|
15.6
|
84.4%
|
